People | June 01, 2026
Ardena appoints Ariane de Ganck as Chief Scientific Officer
Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022
Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
With standout ADC and t-cell engager response data across hard-to-treat cancers
Clears major obesity endpoints at 80 weeks
Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Funding to accelerate development of integrated DNA platform supporting vaccines, gene therapies and advanced biologics
The next-generation proteomics platform powered by Olink™ Explore HT enables simultaneous analysis of thousands of proteins from a single sample
Access to genomic testing, not therapy cost, is the biggest challenge
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
